Uribe-Zúñiga P, Magis-Rodríguez C, Bravo-García E, Gayet-errano C, Villegas-Icazbalceta L, Hernández-Tepichin G

Language: Spanish
References: 35
Page: 255-270
PDF size: 212.01 Kb.

ABSTRACT

The structural conditions of social inequality in that women live are the main factor of their vulnerability. The main vulnerabilities that women affect are biological, epidemic, social and cultural. In the case of the biological vulnerability it has been proven that in the heterosexual relationships, the woman is from 2 to more vulnerable 4 times to the infection for the VIH that the man. For year 2002, the Program of the United Nations Organisation for the Prevention of the AIDS (UNAIDS), estimated that in the world 42 million people are living with the Human Inmunodeficiency Virus (HIV), of those which 19.2 millions (45.9%) are women and 3.2 millions (7.7%) smaller than 15 years. In Latin America and the Caribbean, the number of infections for HIV almost reached the figure of 2 million infections and it has become the second region more affected by the epidemic of the AIDS, with a prevalence of 2.3% in the population. Mexico is located in the twentieth third place in America and the Caribbean, and the place seventy seven at world level. Of the total of accumulated cases, 49,207 (85.4%) correspond to men and 8,433 (14.6%) to women, settling down a relationship man/woman from 6 to 1. However, it can be observed that for the cases of having been diagnosed in the 2002, the proportion of women reached 16.5%. With the introduction of the antiretroviral treatments, the figures of mortality began to diminish in Mexico. For example, the rate of mortality in population of 25 to 34 years, began to diminish in 1997 until reaching a figure of 16.0 for a hundred thousand inhabitants in the year 2001. The decrease in the mortality is associated with the growth in the covering of the antiretroviral treatment. To prevent the perinatal transmission of HIV/AIS and sexual transmitted infections, it is required to detect all infected woman appropriately. For this reason it is indispensable to qualify personnel of health to identify risk factors, to promote the prenatal attention, to provide information and appropriate advice about the importance of these infections and the risk of transmitting them to their children.

REFERENCES

1. Herrera C, Campero L. La vulnerabilidad de las mujeres ante el VIH/SIDA: constantes y cambios en el tema. Salud Pública Mex 2002; 44: 554-64.

2. Giffin K. Beyond empowerment: heterosexualities and prevention of AIDS. Soc Sci Med 1998; 46: 151-6.

3. Oakley A. Sex, gender and society. Londres: Temple Smith; 1972.

4. Rubin G. El tráfico de mujeres: notas sobre la “economía política” del sexo. En: Lamas M. (editora). El género: la construcción cultural de la diferencia sexual. México: Porrúa; 1996, p. 35-96.

5. Joint United Nations Programme on HIV/AIDS (UNAIDS). AIDS Epidemic Update: December 2002. Geneva: UNAIDS, 2000.

6. Joint United Nations Programme on HIV/AIDS (UNAIDS). AIDS Epidemic Update: December 2002. Geneva: UNAIDS, 2000.

7. World Health Organization. The World Health Report 2002. Geneva: World Health Organization, 2002.

8. UNAIDS. AIDS Epidemic Update: December 2002. Geneva: UNAIDS, 2000.

9. Pan American Health Organization (PAHO). HIV and AIDS en the Americas: an epidemic with many faces. Washington: PAHO, 2001.

10. Programa Conjunto de las Naciones Unidas sobre el VIH/SIDA (ONUSIDA). Informe sobre la epidemia mundial de VIH/SIDA 2002. Ginebra: Onusida, 2002.

11. Magis-Rodríguez C, Bravo-García E, Rivera Reyes P. El SIDA en México en el año 2000. En: Uribe P y Magis C. (editores). La respuesta mexicana al SIDA: mejores prácticas. México: SSA, CONASIDA; 2000: p. 13-22.

12. Organización Panamericana de la Salud (OPS). Vigilancia del SIDA en las Américas (Informe bianual). Washington: OPS, 2001.

13. Organización Mundial de la Salud (OMS). ONUSIDA. Guías sobre la vigilancia de VIH de segunda generación. Ginebra: Organización Mundial de la Salud, S/A.

14. Magis Rodríguez C, Bravo-García E, Anaya López L, Uribe Zúñiga P. La situación del SIDA en México a finales de 1998. Enf Infec y Microbiol 1998; 18: 236-44.

15. Magis C, Rivera P, Bravo-García E. People living with HIV estimate in Mexico. XIV Int Conf on HIV-AIDS. Barcelona, 2002.

16. Uribe Zúñiga P, Magis Rodríguez C, Bravo-García E. Aids in Mexico. J Int Assoc Physicians AIDS Care 1998; 4: 29-33.

17. Secretaría de Salud. Subsecretaría de Prevención y Protección a la Salud. Programa de acción: VIH/SIDA e Infecciones de Transmisión Sexual (ITS). México: SSA, 2002.

18. Estimaciones de CENSIDA con base en datos de mortalidad de las Direcciones Generales de Estadística y de Epidemiología de la Secretaría de Salud.

19. Estimaciones de CENSIDA con base en datos del Registro Nacional de Casos de SIDA.

20. World Health Organization. Voluntary Counseling and Testing for HIV Infection in Antenatal Care Practical Considerations for Implementation. Geneva: WHO, January 2000.

21. Secretaría de Salud. CONASIDA. Guía para la Atención Médica de Pacientes con Infección por VIH/SIDA en Consulta Externa y Hospitales, 4a. Edición. México: SSA; 2000, p. 190.

22. Centers for Disease Control and Prevention. U.S. Public Health Service Recommendations for Human Inmunodeficiency Virus Counseling and Voluntary Testing for Pregnant Women. MMWR 1995; 44(RR-7): 1-15.

23. Yvonne J, Bryson MD. Perinatal transmission of HIV: Pathogenesis and therapeutic intervention. Oral Presentation. 3rd Conference on Retroviruses and Opportunistic Infections. Washington DC. January 28-February 1, 1996.

24. Centers for Disease Control and Prevention. Zidovudine for the prevention of HIV transmission from mother to infant. MMWR 1994 April; 43: 285-8.

25. ZDV Reduces Maternal transmission of HIV. Journal of the Physicians Association for AIDS Care 1994: 15-16.

26. Centers for Disease Control and Prevention. Recommendations of the U.S. Public Health Service Task Force on the Use of Zidovudine to Reduce Perinatal Transmission of Human Immunodeficiency Virus. MMWR 1994 August; 43(RR-11): 1-20.

27. Blattner W, Cooper E, Charurat M, et al. Effectiveness of potent antiretroviral therapies on reducing perinatal transmission of HIV1. XIII International AIDS Conference, Durban, South Africa (abstract LbOr4), July 9-14, 2000.

28. Public Health Service Task Force Recommendations for the Use of Antiretroviral Drugs in Pregnant Women Infected With HIV-1 for Maternal Health and for Reducing Perinatal HIV-1 transmission in the United States. February 4, 2002.

29. Public Health Service Task Force Recommendations for the Use of Antiretroviral Drugs in Pregnant Women Infected With HIV-1 for Maternal Health and for Reducing Perinatal HIV-1 Transmission in the United States. August 30, 2002.

30. Organización Mundial de la Salud. Declaración de la Reunión Consultiva Sobre Exámenes y Consejos en la Infección por el VIH. WHO/GPA/INF/93.2.

31. CONASIDA, Guía para el manejo de la mujer embarazada con infección por VIH. 3a. Edición, México: SSA; 2000, p. 33-5.

32. Nicoll A, Newell ML, Van Prag E, Van de Perre P and Peckham C. Infant feeding policy and practice in the presence of HIV-1 infection. AIDS 1995; 9: 107-19.

33. Radolf-Justin, D. Congenital syphilis. STD/HIV in reproductive health and pediatrics. En: Holmes KK, editor. Enfermedades de transmisión sexual. New York: Mc-Graw Hill; 1999, p. 1165-86.

34. Organización Panamericana de la Salud (OPS). El Control de las enfermedades transmisibles. Informe Oficial de Asociación Estadounidense de Salud Pública; 2001, p. 572-3.

35. Valdespino JL, Olaiz G, López-Barajas MP, Palma O, Velásquez O, Tapia R, Sepúlveda J. Encuesta Nacional de Salud 2000. Tomo I. Vivienda, población y utilización de servicios de salud. Cuernavaca, Morelos, México. Instituto Nacional de Salud Pública, 2003.